Includes bibliographical references and index.
|Statement||[edited by] Hisham M. Mehanna, K. Kian Ang ; with contributions by Oludolapo O. Adesanya ... [et al.].|
|The Physical Object|
|ISBN 10||9783131473912, 9783131645715|
|LC Control Number||2012019185|
Head and Neck Cancer Recurrence is the first comprehensive, evidence-based reference on this complex condition, providing state-of-the-art strategies for treating and managing recurrence at each site within the head and neck. With this book at hand, specialists will have guidelines for detecting the presence of a tumor, evaluating the extent. Treatment of patients with locoregional recurrent or second primary head and neck squamous cell cancer (HNSCC) has been guided by well-reasoned principles and informed by carefully tested chemotherapy and radiation regimens. However, clinical decision making for this population is complicated by many factors. Although surgery is generally considered the treatment of choice for Cited by: 8. Head and Neck Cancer: Psychological and Psychosocial Effects will help otolaryngologists, oncologists, surgeons, psychologists and healthcare professionals define the unique issues associated with the HNC patient population, discuss pertinent data, outline key aspects of high quality care in this population, and to draw attention to necessary. Purpose of review: In the last decade, after cetuximab (anti-epidermal growth factor receptor), none of the novel investigated compounds has demonstrated benefit in head and neck squamous cell cancers (HNSCC), both in advanced and curative settings. Therefore, prognosis of recurrent/metastatic (R/M) HNSCC patients remains dismal, especially in platinum-refractory cohort.
Recurrence in people with head and neck cancer related to human papillomavirus (HPV) can expect a better outcome. That’s the case even with . Cancer recurrence is all too common an outcome after treatment of advanced head and neck cancer. Salvage surgery often offers the only chance of survival for the patient; however, few studies have evaluated outcome after salvage surgery, and even within these studies, it is difficult to discern if those patients with initial advanced disease, who are most likely to have a recurrence, can be. People who have been treated for head and neck cancers have an increased chance of developing a new cancer, usually in the head, neck, esophagus, or lungs. The chance of a second primary cancer varies depending on the site of the original cancer, but it . Cancer recurrence is a foremost concern of patients and Am Soc Clin Oncol Educ Book prognostic factors and survival in locoregionally advanced head and neck cancer treated with.
This study is clinical trials of BNCT for head and neck cancers. • BNCT was performed in 20 advanced/recurrent head and neck cancer patients. • The effective rate [(CR+PR)/total cases] was 90%. • BNCT is effective the patients with radio resistance head and neck cancer. • BNCT is a potential curative therapy for patients with head and. The majority of immune therapy in head and neck cancer has so far focused on removal of the negative regulatory immune pathways. Many ongoing studies are investigating the role of immune checkpoint inhibitors in recurrent/metastatic head and neck cancer, including single agent and combination of checkpoint inhibitors as dual-inhibition, combination with immunomodulators, vaccines, Cited by: 8. Head and neck cancer recurrence is always a possibility, so it is essential for a patient to remain vigilant for symptoms even after completing an initial round of treatment. This includes seeing a physician for regular checkups as well as any time a potential sign of recurrence develops. Recurrent cancer can form at or near the original site. MSKCC; PMID — "Salvage re-irradiation for recurrent head and neck cancer." (Lee N, Int J Radiat Oncol Biol Phys. Jul 1;68(3)) pts w/ recurrent HNSCC. Median time from previous RT 38 mo (all >5 mo). Median previous dose 62 Gy.